CONNIE J. BEEHLER, M.D.; JUDY R. BECKNER, M.D.; ROBERT C. ROSENQUIST, M.D.; STEWART W. SHANKEL, M.D.
Many of the toxic manifestations of chronic renal failure have been directly attributed to hyperparathyroidism, an almost constant feature of chronic renal failure (1). Hyperparathyroidism in chronic renal failure is believed to be secondary to retention of phosphate (2) and decreased production of calcitriol by the impaired kidney (3).
Phosphate binders, a low phosphate diet, calcium, calcitriol, and intensive hemodialysis have all been used to prevent the development of hyperparathyroidism in renal failure. Despite these measures, most patients undergoing chronic hemodialysis still have marked elevations of parathyroid hormone (PTH), and some need a subtotal parathyroidectomy. Clearly, more effective ways to
BEEHLER CJ, BECKNER JR, ROSENQUIST RC, SHANKEL SW. Parathyroid Hormone Suppression by Cimetidine in the Uremic Patient. Ann Intern Med. ;93:840–841. doi: 10.7326/0003-4819-93-6-840
Download citation file:
Published: Ann Intern Med. 1980;93(6):840-841.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use